Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File No. 001-39256

RESEARCH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)


Nevada	11-3797644
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Address not applicable¹	N/A
(Address of principal executive offices)	(Zip Code)

(310) 477-0354

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each Class	Trading Symbol(s)	Name of each Exchange on which registered
Common stock, $0.001 par value	RSSS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer þ	Smaller reporting company þ
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.


Title of Class		Number of Shares Outstanding on February 5, 2024
Common Stock, $0.001 par value		32,620,507

¹ In November 2019, we became a fully remote company. Accordingly, we do not currently have principal executive offices.

Table of Contents

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION	3
Item 1. Condensed Consolidated Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3. Quantitative and Qualitative Disclosures About Market Risk	34
Item 4. Controls and Procedures	34

PART II — OTHER INFORMATION	35
Item 1A. Risk Factors	35
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 6. Exhibits	36

SIGNATURES	37

Table of Contents

PART 1 — FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets


	December 31,
	2023		June 30,
	(unaudited)		2023
Assets
Current assets:
Cash and cash equivalents	$	2,697,659	$	13,545,333
Accounts receivable, net of allowance of $94,991 and $85,015, respectively		7,289,248		6,153,063
Prepaid expenses and other current assets		547,786		400,340
Prepaid royalties		1,081,578		1,202,678
Total current assets		11,616,271		21,301,414

Non-current assets:
Property and equipment, net of accumulated depreciation of $905,411 and $881,908, respectively		103,195		70,193
Intangible assets, net of accumulated amortization of $940,234 and $747,355, respectively ($10,806,487 provisional)		11,290,225		462,068
Goodwill (provisional)		16,451,937		—
Deposits and other assets		1,060		1,052
Total assets	$	39,462,688	$	21,834,727

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	8,862,829	$	8,079,516
Deferred revenue		7,843,674		6,424,724
Total current liabilities		16,706,503		14,504,240

Non-current liabilities:
Contingent earnout liability		8,792,811		—
Total liabilities		25,499,314		14,504,240

Commitments and contingencies

Stockholders’ equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding		—		—
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,619,598 and 29,487,508 shares issued and outstanding, respectively		32,620		29,487
Additional paid-in capital		37,607,895		29,941,873
Accumulated deficit		(23,564,320)		(22,522,649)
Accumulated other comprehensive loss		(112,821)		(118,224)
Total stockholders’ equity		13,963,374		7,330,487
Total liabilities and stockholders’ equity	$	39,462,688	$	21,834,727

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2023		2022		2023		2022

Revenue:
Platforms	$	3,125,584	$	2,110,272	$	5,725,776	$	4,130,239
Transactions		7,188,158		6,606,394		14,648,937		13,271,070
Total revenue		10,313,742		8,716,666		20,374,713		17,401,309

Cost of revenue:
Platforms		486,185		253,073		868,799		483,546
Transactions		5,343,755		5,059,766		10,990,546		10,164,688
Total cost of revenue		5,829,940		5,312,839		11,859,345		10,648,234
Gross profit		4,483,802		3,403,827		8,515,368		6,753,075

Operating expenses:
Selling, general and administrative		4,748,050		3,726,928		9,818,948		6,890,735
Depreciation and amortization		155,749		6,342		215,369		12,154
Total operating expenses		4,903,799		3,733,270		10,034,317		6,902,889

Loss from operations		(419,997)		(329,443)		(1,518,949)		(149,814)

Other income		376,426		74,695		516,737		113,764

Loss from operations before provision for income taxes		(43,571)		(254,748)		(1,002,212)		(36,050)
Provision for income taxes		(10,057)		(782)		(39,459)		(4,915)

Net loss		(53,628)		(255,530)		(1,041,671)		(40,965)

Other comprehensive income (loss):
Foreign currency translation		6,349		6,524		5,403		1,348
Comprehensive loss	$	(47,279)	$	(249,006)	$	(1,036,268)	$	(39,617)

Loss per common share:
Net loss per share, basic and diluted	$	-	$	(0.01)	$	(0.04)	$	-
Weighted average common shares outstanding, basic and diluted		28,092,945		26,816,550		27,564,404		26,767,360

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Six Months Ended December 31, 2023

(Unaudited)


				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity

Balance, September 30, 2023	29,624,085	$	29,624	$	30,487,415	$	(23,510,692)	$	(119,170)	$	6,887,177

Fair value of vested stock options	—		—		44,243		—		—		44,243

Fair value of vested restricted common stock	275,000		275		530,988		—		—		531,263

Repurchase of common stock	(8,501)		(8)		(22,605)		—		—		(22,613)

Common stock issued for acquisition of Scite	2,729,014		2,729		6,546,905		—		—		6,549,634

Modification cost of accelerated vesting of restricted common stock	—		—		20,949		—		—		20,949

Net loss for the period	—		—		—		(53,628)		—		(53,628)

Foreign currency translation	—		—		—		—		6,349		6,349

Balance, December 31, 2023	32,619,598	$	32,620	$	37,607,895	$	(23,564,320)	$	(112,821)	$	13,963,374

Balance, July 1, 2023	29,487,508	$	29,487	$	29,941,873	$	(22,522,649)	$	(118,224)	$	7,330,487

Fair value of vested stock options	—		—		61,714		—		—		61,714

Fair value of vested restricted common stock	380,000		380		1,105,226		—		—		1,105,606

Repurchase of common stock	(27,104)		(27)		(68,721)		—		—		(68,748)

Common stock issued upon exercise of stock options	50,180		51		(51)		—		—		—

Common stock issued for acquisition of Scite	2,729,014		2,729		6,546,905		—		—		6,549,634

Modification cost of accelerated vesting of restricted common stock	—		—		20,949		—		—		20,949

Net loss for the period	—		—		—		(1,041,671)		—		(1,041,671)

Foreign currency translation	—		—		—		—		5,403		5,403

Balance, December 31, 2023	32,619,598	$	32,620	$	37,607,895	$	(23,564,320)	$	(112,821)	$	13,963,374

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Six Months Ended December 31, 2022

(Unaudited)


				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity

Balance, September 30, 2022	27,330,878	$	27,331	$	28,298,171	$	(22,879,707)	$	(127,117)	$	5,318,678

Fair value of vested stock options	—		—		261,031		—		—		261,031

Fair value of vested restricted common stock	1,800,000		1,800		345,872		—		—		347,672

Repurchase of common stock	(16,141)		(16)		(30,651)		—		—		(30,667)

Common stock issued upon exercise of stock options	40,000		40		(40)		—		—		—

Net loss for the period	—		—		—		(255,530)		—		(255,530)

Foreign currency translation	—		—		—		—		6,524		6,524

Balance, December 31, 2022	29,154,737	$	29,155	$	28,874,383	$	(23,135,237)	$	(120,593)	$	5,647,708

Balance, July 1, 2022	27,075,648	$	27,076	$	28,072,855	$	(23,094,272)	$	(121,941)	$	4,883,718

Fair value of vested stock options	—		—		301,737		—		—		301,737

Fair value of vested restricted common stock	2,022,334		2,022		480,305		—		—		482,327

Fair value of vested unrestricted common stock	36,509		36		68,236		—		—		68,272

Repurchase of common stock	(25,800)		(25)		(48,704)		—		—		(48,729)

Common stock issued upon exercise of stock options	46,046		46		(46)		—		—		—

Net loss for the period	—		—		—		(40,965)		—		(40,965)

Foreign currency translation	—		—		—		—		1,348		1,348

Balance, December 31, 2022	29,154,737	$	29,155	$	28,874,383	$	(23,135,237)	$	(120,593)	$	5,647,708

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended
	December 31,
	2023		2022

Cash flow from operating activities:
Net loss	$	(1,041,671)	$	(40,965)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		215,369		12,154
Fair value of vested stock options		61,714		301,737
Fair value of vested restricted common stock		1,105,606		482,327
Fair value of vested unrestricted common stock		—		68,272
Modification cost of accelerated vesting of restricted common stock		20,949		—
Changes in operating assets and liabilities:
Accounts receivable		(681,502)		8,159
Prepaid expenses and other current assets		(67,986)		(67,603)
Prepaid royalties		121,100		805,436
Accounts payable and accrued expenses		81,078		(974,931)
Deferred revenue		(241,545)		428,999
Net cash provided by (used in) operating activities		(426,888)		1,023,585

Cash flow from investing activities:
Purchase of property and equipment		(55,763)		(18,876)
Payment for acquisition of Resolute, net of cash acquired		(2,718,253)		—
Payment for acquisition of Scite, net of cash acquired		(7,305,493)		—
Payment for non-refundable deposit for asset acquisition		—		(297,450)
Net cash used in investing activities		(10,079,509)		(316,326)

Cash flow from financing activities:
Common stock repurchase		(68,748)		(48,729)
Payment of contingent acquisition consideration		(278,195)		—
Net cash used in financing activities		(346,943)		(48,729)

Effect of exchange rate changes		5,666		859
Net increase (decrease) in cash and cash equivalents		(10,847,674)		659,389
Cash and cash equivalents, beginning of period		13,545,333		10,603,175
Cash and cash equivalents, end of period	$	2,697,659	$	11,262,564

Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	39,459	$	4,915

Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$	36,364	$	—

See notes to condensed consolidated financial statements

Table of Contents

RESEARCH SOLUTIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Six Months Ended December 31, 2023 and 2022 (Unaudited)

Note 1. Organization, Nature of Business and Basis of Presentation

Organization

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with five wholly owned subsidiaries: Reprints Desk, Inc., (“Reprints Desk”) a Delaware corporation, including its wholly owned subsidiary Resolute Innovation, Inc., a Delaware corporation, Scite, LLC., a Delaware Limited Liability Company, Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Nature of Business

We provide software and related services to help research intensive organizations save time and money. We offer various software platforms (“Platform” or “Platforms”) that are typically sold to corporate, academic, government and individual researchers as cloud-based software-as-a-service (“SaaS”) via auto-renewing license agreements. Corporate, academic, and government customers typically sign up under annual agreements. Individual researchers can sign up under an annual or a month-to-month agreement and are typically billed monthly. Our Platforms also facilitate the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via one or more of the research Platform solutions we provide. When one or more of the Platform solutions are used to purchase Transactions, customers pay for those transactions through monthly billing or via credit card for individual researchers. Our Platforms enable life science and other research-intensive organizations to accelerate their research and development activities through our advanced discovery tools (i.e. search), tools to access and buy STM articles required to support their research (i.e. acquire), as well as tools that manage that content across the enterprise and on an individual basis (i.e. manage). The Platforms typically deliver an ROI to the customer by reducing the amount of time it takes a research organization to find, acquire and manage content, in addition to also driving down the ultimate cost per article over time.

Platforms

Our cloud-based SaaS Platforms consist of proprietary software and Internet-based interfaces sold to customers through an annual or monthly subscription fee. Legacy functionality falls into three areas.

Discover – These solutions facilitate search (discovery) across virtually all STM articles available. The solutions we offer include free (basic) search solutions and advanced search tools like the Resolute.ai and scite.ai products. These tools allow for searching and identifying relevant research and then purchasing that research through one of our other solutions. In addition, these tools increasingly enable users to find insights in other datasets adjacent to STM content, such as Clinical Trial, Patent, Life Science & MedTech Regulatory information, Competitor and Technology landscape insights in addition to searching the customer’s internal datasets. The advanced search solutions are sold through a seat, enterprise, or individual license.

Acquire – Our Article Galaxy (AG) solution allows for research organizations to load their entitlements (subscriptions, discount or token packages, and their existing library of articles) and AG manages those entitlements in the background enabling the researchers to focus on acquiring articles they need quickly and efficiently at the lowest possible cost. When used in conjunction with our discovery Platforms, customers can initiate orders, route orders based on the lowest cost to acquire, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems.

Manage – Our References solution allows users to access the article inside the Platform including setting up personal folders or team folders and allows researchers to markup and take notes on the articles in a supported browser on a desktop or tablet.

Table of Contents

We use Artificial Intelligence (“AI”) in several parts of the research workflow today and will continually add capability as we move forward. Today we offer an AI based recommendation engine in our Discover, Acquire, and Manage Platform solutions. We also offer an AI based “assistant” in some of our solutions to allow the researcher to ask questions about articles, groups of articles (folders), and more. We also have the capability to provide full text search on STM content in the scite.ai Platform where the publisher gives us the rights to do so.

Using Resolute.ai and scite.ai technology, we plan to release several new Platform solutions to enhance the research workflows described above and add new solutions to support the analysis functions that exist in our typical customer base.

Our Platforms are deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform efficiencies in scalability, stability and development costs to fuel rapid innovation and to gain a competitive advantage.

Transactions

We provide our researchers with a single source to the universe of published STM content that includes over 100 million existing STM articles and over 2 to 4 million newly published STM articles each year. STM content is sold to our customers on a per transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users and while they typically purchase the articles via one of our Platform solutions, we do have some customers that just order articles from us on behalf of end-users in their organizations.

Core to many of our Platform solutions is providing our customers with ways to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour; in most cases under one minute. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes. While a vast majority of the articles are available in electronic form, the Company also has workflows to deliver older paper-based articles through relationships we have built with libraries around the world.

Principles of Consolidation

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2023 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

Table of Contents

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, impairment related to intangible assets, useful lives of finite-lived intangible assets, and realization of deferred tax assets.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $447,269 and $1,760,323 at December 31, 2023 and June 30, 2023, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at December 31, 2023 and June 30, 2023.

The following table summarizes vendor concentrations:


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2023		2022		2023		2022
Vendor A	26	%	21	%	25	%	21	%
Vendor B	10	%	13	%	11	%	12	%

Revenue Recognition

The Company accounts for revenue in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium

Table of Contents

features of our cloud-based SaaS research intelligence platforms (Platforms) and the transactional sale of STM content managed, sourced and delivered through the Platform (Transactions).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platforms. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	December 31,
	2023				2022
United States	$	6,070,189	58.9	%	$	5,061,779	58.1	%
Europe		3,301,660	32.0	%		2,963,155	34.0	%
Rest of World		941,893	9.1	%		691,732	7.9	%
Total	$	10,313,742	100	%	$	8,716,666	100	%

Table of Contents


	Six Months Ended
	December 31,
	2023				2022
United States	$	11,931,113	58.6	%	$	10,104,860	58.1	%
Europe		6,457,252	31.7	%		5,972,746	34.3	%
Rest of World		1,986,348	9.7	%		1,323,703	7.6	%
Total	$	20,374,713	100	%	$	17,401,309	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of December 31, 2023				As of June 30, 2023
United States	$	3,989,404	54.7	%	$	3,727,977	60.6	%
Europe		2,317,166	31.8	%		1,763,044	28.7	%
Rest of World		982,678	13.5	%		662,042	10.8	%
Total	$	7,289,248	100	%	$	6,153,063	100	%

Business Combinations

The Company accounts for its business combinations using the acquisition method of accounting where the purchase consideration is allocated to the tangible and intangible assets acquired, and liabilities assumed, based on their respective fair values as of the acquisition date. The excess of the fair value of the purchase consideration over the estimated fair values of the net assets acquired is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.

Intangible Assets

Amortizable finite-lived identifiable intangible assets consist of a developed technology and customer relationships acquired in the acquisition of ResoluteAI effective July 28, 2023 and Scite effective December 1, 2023 (See Note 5), and are stated at cost less accumulated amortization. The developed technology and customer relationships are being amortized over the estimated average useful lives of 3 to 10 years. The Company follows ASC 360 in accounting for finite-lived intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. As of December 31, 2023, the Company determined there were no indicators of impairment of its intangible assets.

Goodwill

Goodwill consists of the excess of the cost of ResoluteAI and Scite (see Note 5) over the fair value of amounts assigned to assets acquired and liabilities assumed. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. The Company’s policy is to perform an annual impairment testing for its reporting units on June 30 of each fiscal year.

Table of Contents

Deferred Revenue

Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer.

Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

Foreign Currency

The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gains of $13,738 and $84,179 for the three months ended December 31, 2023 and 2022, respectively and gains of $7,118 and $11,663 for the six months ended December 31, 2023 and 2022, respectively. Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $447,269 and $1,760,323 at December 31, 2023 and June 30, 2023, respectively, was held in accounts at financial institutions located in Europe.

Table of Contents

The following table summarizes the exchange rates used:


	Six Months Ended		Year Ended
	December 31,		June 30,
	2023	2022	2023	2022
Period end Euro : US Dollar exchange rate	1.10	1.07	1.09	1.05
Average period Euro : US Dollar exchange rate	1.08	1.01	1.05	1.13

Period end GBP : US Dollar exchange rate	1.27	1.21	1.27	1.21
Average period GBP : US Dollar exchange rate	1.25	1.17	1.20	1.34

Period end Mexican Peso : US Dollar exchange rate	0.06	0.05	0.06	0.05
Average period Mexican Peso : US Dollar exchange rate	0.06	0.05	0.05	0.05

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At December 31, 2023 potentially dilutive securities include options to acquire 2,847,958 shares of common stock and unvested restricted common stock of 2,679,224. At December 31, 2022 potentially dilutive securities include options to acquire 3,070,224 shares of common stock and unvested restricted common stock of 2,300,283. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

Basic and diluted net loss per common share is the same for the three and six months ended December 31, 2023 and 2022 because all stock options, warrants, and unvested restricted common stock are anti-dilutive.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company adopted this standard effective July 1, 2023, and there was no material impact of adopting this standard on the Company’s financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Note 3. Line of Credit

The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 28, 2024, and is subject to certain financial and performance covenants with which we were in compliance as of December 31, 2023. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and

Table of Contents

5.0%. The interest rate on the line of credit was 9.5% as of December 31, 2023. The line of credit is secured by the Company’s consolidated assets.

Pursuant to the Amended and Restated Loan and Security Agreement dated October 31, 2017 among the Company, Reprints Desk, Inc. and SVB (the “SVB LSA”), the Company was required to direct account debtors to deliver or transmit all proceeds of accounts remitted to the Company and its subsidiaries into a lockbox account as specified by SVB, and to maintain its and its subsidiaries’ primary operating and other deposit accounts with SVB.

There were no outstanding borrowings under the line as of December 31, 2023 and June 30, 2023, respectively. As of December 31, 2023, there was approximately $2,426,000 of available credit. On March 27, 2023, First Citizens BancShares, Inc. (“FCB”) entered into an agreement with the Federal Deposit Insurance Corporation (FDIC) to purchase all of the assets and liabilities of SVB. The Company has confirmed that the Loan and Security Agreement remains in effect post this transaction and that, it continues to have access to the revolving line of credit.

SVB Bridge Bank agreed that the Company can lower its cash balance threshold requirement associated with the SVB LSA, reducing the required balances of its and its subsidiaries’ primary operating and other accounts with SVB, and the Company continues to evaluate the SVB LSA. The Company has established additional banking relationships with Bank of America, N.A. and PNC Bank, N.A. At December 31, 2023, the Company held cash at Bank of America, N.A. of $124,044 and at PNC Bank, N.A. of $136,730.

Subsequent to September 30, 2023, FCB informed the Company of certain defaults under the SVB LSA resulting from the Company’s violation of certain covenants regarding retaining operating cash with SVB, obtaining deposit account control agreements with respect to such accounts and failing to maintain the required adjusted quick ratio. The Company became aware of additional technical defaults following FCB’s outreach, and such defaults substantially related to the Company’s moves to promptly diversify its cash position following the collapse of Silicon Valley Bank in March of 2023. On November 14, 2023, the Company, Reprints Desk and FCB entered into a Fifth Amendment to Amended and Restated Loan and Security Agreement, Consent and Forbearance Agreement (the “Fifth Amendment”) pursuant to which, among other matters, FCB agreed to forbear from exercising its remedies under the SVB LSA in connection with the existing events of default, and agreed to waive the existing events of default provided the Company regains compliance with the adjusted quick ratio covenant and the operating accounts covenants by January 30, 2024, no other events of defaults have occurred and no forbearance termination events (as listed in the Fifth Amendment) have occurred.

Note 4. Stockholders’ Equity

Stock Options

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 17, 2020, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 2,374,513 to 3,374,513. On November 17, 2021, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 3,374,513 to 6,874,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of December 31, 2023, there were 857,993 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made

Table of Contents

under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

The following table summarizes vested and unvested stock option activity:


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2023	2,909,574	$	1.87	2,865,593	$	1.86	43,981	$	2.47
Granted	257,934		2.73	—		—	257,934		2.73
Options vesting	—		—	26,137		2.44	(26,137)		2.44
Exercised	(319,550)		2.03	(319,550)		2.03	—		—
Forfeited	—		—	—		—	—		—
Outstanding at December 31, 2023	2,847,958	$	1.93	2,572,180	$	1.84	275,778	$	2.72

The weighted average remaining contractual life of all options outstanding as of December 31, 2023 was 5.53 years. The remaining contractual life for options vested and exercisable at December 31, 2023 was 5.07 years. Furthermore, the aggregate intrinsic value of options outstanding as of December 31, 2023 was $2,076,104, and the aggregate intrinsic value of options vested and exercisable as of December 31, 2023 was $2,073,707, in each case based on the fair value of the Company’s common stock on December 31, 2023.

During the six months ended December 31, 2023, the Company granted 257,934 options to directors with a fair value of $340,473 which amount will be amortized over the vesting period. The total fair value of options that vested during the six months ended December 31, 2023 was $61,714 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of December 31, 2023, the amount of unvested compensation related to stock options was $335,335 which will be recorded as an expense in future periods as the options vest. During the six months ended December 31, 2023, the Company issued 50,180 net shares of common stock upon the exercise of options underlying 319,550 shares of common stock.

Table of Contents

The following table presents the information regarding stock options outstanding and exercisable as of December 31, 2023:


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.93	225,000
	0.77	25,000	0.63	25,000
	0.80	16,000	1.64	16,000
	0.90	15,000	1.59	15,000
	1.00	15,000	1.19	15,000
	1.05	305,000	2.65	305,000
	1.09	40,000	2.40	40,000
	1.10	105,000	1.50	105,000
	1.20	274,000	3.55	274,000
	1.59	25,000	4.36	25,000
	2.10	238,767	8.11	238,767
	2.13	216,708	6.88	216,708
	2.15	200,000	8.95	200,000
	2.17	35,955	7.36	32,958
	2.19	5,000	8.05	3,333
	2.40	302,833	4.87	302,833
	2.43	61,250	7.43	58,750
	2.45	98,000	6.59	98,000
	2.49	78,435	6.42	78,435
	2.50	20,000	5.38	20,000
	2.64	30,882	7.60	25,734
	2.67	33,194	7.72	27,662
	2.73	257,934	9.94	—
	2.99	8,000	6.37	8,000
	3.13	208,000	5.87	208,000
	3.50	8,000	6.12	8,000
	Total	2,847,958		2,572,180

Restricted Common Stock

Prior to July 1, 2023, the Company issued 5,184,592 shares of restricted common stock to employees valued at $7,503,186, of which 2,427,309 shares have vested, 279,489 shares with fair value of $312,156 have been forfeited, and $4,479,369 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 2,477,794 at June 30, 2023, with an aggregate fair value of $2,711,661.

Table of Contents

During the six months ended December 31, 2023, the Company issued an additional 308,000 shares of restricted stock to employees with an aggregate fair value of $860,650. Of this amount, 130,000 shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of these stock awards was $352,450 based on the market price of our common stock ranging from $2.24 to $2.73 per share on the date of grant, which will be amortized over the range of a three year vesting period. The remaining 250,000 shares were granted, under the 2017 Plan, as restricted stock awards to key management in accordance with its long-term equity bonus program (the “LTEBP”). The LTEBP replaces the previous restricted stock compensation program for executives. It spans 5 years and is designed to better serve stockholder interests by aligning key executive compensation with stockholder value. Awards under the LTEBP will vest as follows, upon the 30-day volume weighted average price (VWAP) of our common stock reaching the following targets:

•20% at a 30-day VWAP of $3.00 per share;

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

Upon a change of control, vesting will accelerate with respect to that portion of the award that would vest if the target 30-day VWAP was achieved at the level above the per share price in such change of control transaction. For example, if we granted an award of 100,000 shares under the LTEBP, 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.00 per share, and 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.75 per share. If the per share price in a change of control transaction was $5.00 per share, vesting would accelerate for 40,000 shares under the same award (i.e. the number of shares that would vest for our stock price achieving a 30-day VWAP of $5.25 per share, pursuant to a tier round up provision in the Plan effective upon a change in control). As a condition to receiving awards under the LTEBP, recipients will be required to hold at least 75% of all vested shares during the term of their employment. Applicable target 30-day VWAPs must be achieved within 5 years following the grant of awards under the LTEBP, and all unvested awards under the LTEBP will be forfeited upon expiration of such 5-year period. Recipients will also forfeit unvested awards in the event their service with our company terminates for any reason.

As the vesting of the 250,000 shares of restricted common stock under the LTEBP is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value to be $508,200, computed using the Monte Carlo simulations on a binomial model with the assistance of a valuation specialist with a derived service period ranging from 0.68 to 2.51 years. The total fair value of restricted common stock vesting and expenses related to amortization of the fair value of the LTEBP program during the six months ended December 31, 2023 was $1,126,555 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of December 31, 2023, the amount of unvested compensation related to issuances of restricted common stock was $2,445,756, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. When calculating net loss per share, the 2,679,224 shares are considered antidilutive and are excluded from that calculation.

The following table summarizes restricted common stock activity:


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2023	2,477,794	$	2,711,661	$	1.52
Granted	380,000		860,650		2.26
Vested	(178,570)		(1,126,555)		2.08
Forfeited	—		—		—
Non-vested, December 31, 2023	2,679,224	$	2,445,756	$	1.59

Table of Contents

Common Stock Repurchases

Effective as of February 9, 2021, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2021 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The Compensation Committee of our Board of Directors subsequently approved the extension of the repurchases under the same terms through the end of fiscal year 2024. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. As of June 30, 2023, $151,095 remained under the current authorization to repurchase our outstanding common stock from our employees.

During the six months ended December 31, 2023, the Company repurchased 27,104 shares of our common stock from employees at an average market price of approximately $2.54 per share for an aggregate amount of $68,748. As of December 31, 2023, $82,347 remains under the current authorization to repurchase our outstanding common stock from our employees.

Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

Note 5. Acquisitions

FIZ

On September 28, 2022, Reprints Desk entered into an asset purchase agreement with FIZ Karlsruhe – Leibniz-Institut für Informationsinfrastruktur GmbH (“FIZ”). FIZ delivers STM content pursuant to various contracts with its customers through its AutoDoc platform. FIZ agreed to assign and transfer to Reprints Desk certain of these contracts effective January 1, 2023 (the “Sold Contracts”).

On September 30, 2022, Reprints Desk made a non-refundable payment of $297,450 (€300,000) (the “Base Amount”) as initial consideration for the asset purchase. As of December 31, 2023, Reprints Desk has paid $64,578 in contingent consideration for customers that have their Sold Contracts assumed by Reprints Desk in comparison to the trailing twelve months of revenue of all Sold Contracts (the “Base Amount Plus”). As of December 31, 2023, $88,522 in contingent consideration was recorded for customers that placed an order and have consented to have their contract assumed by Reprints Desk (the “Bonus Amount”). As of December 31, 2023, $96,121 and $42,911 of Bonus Amount payments were made for the 2023 fiscal year and 2024 fiscal year, respectively. The Bonus Amount is based upon the collectable service fee that FIZ would have received from these customers. Contingent consideration for the Bonus Amount will continue to be paid in arrears through the quarter ending December 31, 2025.

The current contingent consideration for the Base Amount Plus and the Bonus Amount is recorded as a short-term liability on the balance sheet. At December 31, 2023, the Base Amount, the Base Amount Plus and the Bonus Amount were recorded as intangible assets on the balance sheet with an estimated average useful life of 10 years.

ResoluteAI

On July 28, 2023, the Company acquired 100% of the outstanding stock of Resolute Innovation, Inc. (“ResoluteAI”), a Delaware corporation, an advanced search platform that equips organizations with search, discovery and knowledge management tools that are powered by artificial intelligence (“AI”) and neuro-linguistic programming (“NLP”) technologies.

The Company utilized the acquisition method of accounting for the acquisition in accordance with ASC 805, Business Combinations. The Company allocated the purchase price to ResoluteAI’s tangible assets, identifiable intangible assets, and assumed liabilities at their estimated fair values as of the date of acquisition. The excess of the purchase price paid by the Company over the estimated fair value of identified tangible and intangible assets has been recorded as provisional goodwill.

Table of Contents

The total purchase consideration for ResoluteAI, net of cash acquired, was approximately $4.6 million. The consideration includes an initial payment of $2.7 million and a contingent earnout that has a fair value of $1.6 million as of December 31, 2023. The contingent earnout payment will be based upon the product of three and one half multiplied by ending annual recurring revenue as of January 31, 2025 less the agreed upon Enterprise Value of $3.4 million.

The Company’s allocation of the purchase price at December 31, 2023 included $0.2 million of receivables, $0.1 million of other assets, $2.1 million of provisional intangible assets and $3.2 million of provisional goodwill. The intangible assets acquired are developed technology and customer relationships with estimated average useful lives of 8 to 10 years. The Company also assumed $0.2 million of payables, $0.6 million of deferred revenue and $0.2 million of other liabilities as part of the acquisition.

The preliminary allocation of purchase price to the assets acquired and liabilities assumed was based upon the estimated fair values at the date of acquisition. As of December 31, 2023, the Company has not completed its analysis for estimating the fair value of the assets acquired and liabilities assumed.

Scite

On December 1, 2023, the Company acquired 100% of the outstanding stock of Scite, Inc. a Delaware corporation (“Scite”), a platform for discovering and evaluating scientific articles via Smart Citations. Smart Citations allow users to see how a publication has been cited by providing the context of the citation and a classification describing whether it allows for supporting or contrasting evidence for the cited claim.

The total purchase consideration for Scite, net of cash acquired, was approximately $20.9 million. The consideration includes an initial payment of $7.2 million in cash, $6.3 million in stock, a holdback of $0.2 million and a contingent earnout that has a fair value of $7.2 million as of December 31, 2023.

The Company’s allocation of the purchase price at December 31, 2023 included $0.1 million of receivables, $8.9 million of provisional intangible assets and $13.1 million of provisional goodwill. The intangible assets acquired are developed technology and customer relationships with estimated average useful lives of 3 to 10 years. The Company also assumed $1.2 million of deferred revenue as part of the acquisition.

Table of Contents

The following sets out the unaudited pro forma operating results for the three and six months ended December 31, 2023 and 2022 for the Company had the acquisition occurred as of July 1, 2022. These amounts include amortization of intangible assets:


	Pro Forma (Unaudited)				Pro Forma (Unaudited)
	Three Months ended December 31,				Six Months ended December 31,
	2023		2022		2023		2022

Revenue	$	11,033,441	$	8,793,998	$	21,834,349	$	17,663,493
Cost of revenue		5,877,494		5,363,807		11,967,550		10,742,750
Gross profit		5,155,947		3,430,191		9,866,799		6,920,743

Total operating expenses		5,524,052		4,031,029		11,197,427		7,461,089

Loss from operations		(368,105)		(600,838)		(1,330,628)		(540,346)

Other income		376,426		74,695		516,737		113,764

Income (loss) from operations before provision for income taxes		8,321		(526,143)		(813,891)		(426,582)
Provision for income taxes		(10,057)		(782)		(39,459)		(4,915)

Pro Forma Net loss	$	(1,736)	$	(526,925)	$	(853,350)	$	(431,497)
Pro Forma Net loss per weighted average share, basic and diluted	$	-	$	(0.02)	$	(0.03)	$	(0.02)

Note 6. Contingencies

Inflation Risk

The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

Note 7. Subsequent Events

On January 5, 2024, the Company issued 909 net shares of common stock upon the exercise of stock options underlying 7,500 shares of common stock on a cashless basis.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations for the three and six months ended December 31, 2023 and 2022 should be read in conjunction with our consolidated financial statements and related notes to those financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements.

Overview

Research Solutions was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with five wholly owned subsidiaries as of December 31, 2023: Reprints Desk, Inc., a Delaware corporation, including its wholly owned subsidiary Resolute Innovation, Inc., a Delaware corporation, Scite, LLC., a Delaware Limited Liability Company, Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Platforms

Table of Contents

Transactions

Inflation Risk

We do not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that our operating costs could become subject to inflationary and interest rate

Table of Contents

pressures in the future, which would have the effect of increasing our operating costs, and which would put additional stress on our working capital resources.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions.

The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to an understanding of our financial statements because they inherently involve significant judgments and uncertainties.

Revenue Recognition

We account for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We derive our revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platforms (Platforms) and the transactional sale of STM content managed, sourced and delivered through the Platform (Transactions).

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Table of Contents

Platforms

Transactions

Stock-Based Compensation

The fair value of our stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Recent Accounting Pronouncements

Please refer to footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q for a discussion of Recent Accounting Pronouncements.

Quarterly Information (Unaudited)

The following table sets forth unaudited and quarterly financial data for the most recent eight quarters:


	Dec. 31,		Sept. 30,		June 30,		Mar. 31,		Dec. 31,		Sept. 30,		June 30,		Mar. 31,
	2023		2023		2023		2023		2022		2022		2022		2022
Revenue:
Platforms	$	3,125,584	$	2,600,192	$	2,303,375	$	2,249,632	$	2,110,272	$	2,019,967	$	1,886,845	$	1,786,224
Transactions		7,188,158		7,460,779		7,656,342		8,092,794		6,606,394		6,664,676		6,675,164		6,971,128
Total revenue		10,313,742		10,060,971		9,959,717		10,342,426		8,716,666		8,684,643		8,562,009		8,757,352

Cost of revenue:
Platforms		486,185		382,615		275,110		268,630		253,073		230,473		240,214		219,051
Transactions		5,343,755		5,646,791		5,764,064		6,046,523		5,059,766		5,104,922		5,038,653		5,299,804
Total cost of revenue		5,829,940		6,029,406		6,039,174		6,315,153		5,312,839		5,335,395		5,278,867		5,518,855

Gross profit:
Platforms		2,639,399		2,217,577		2,028,265		1,981,002		1,857,199		1,789,494		1,646,631		1,567,173
Transactions		1,844,403		1,813,988		1,892,278		2,046,271		1,546,628		1,559,754		1,636,511		1,671,324
Total gross profit		4,483,802		4,031,565		3,920,543		4,027,273		3,403,827		3,349,248		3,283,142		3,238,497

Operating expenses:
Sales and marketing		804,927		685,016		455,030		642,624		666,608		521,216		691,368		543,496
Technology and product dev.		1,336,558		1,244,579		991,093		953,677		922,132		875,290		1,049,430		971,959
General and administrative		2,023,848		2,542,868		1,649,333		1,871,590		1,613,664		1,519,424		1,663,671		1,629,371
Depreciation and amortization		155,749		59,620		22,163		18,332		6,342		5,812		5,507		4,988
Stock-based comp. expense		596,455		591,814		585,384		480,458		608,703		175,361		225,501		399,234
Foreign currency transaction loss (gain)		(13,738)		6,620		(37,743)		(72,547)		(84,179)		72,516		91,279		29,394
Total operating expenses		4,903,799		5,130,517		3,665,260		3,894,134		3,733,270		3,169,619		3,726,756		3,578,442
Other income (expenses and income taxes)		366,369		110,909		120,463		103,703		73,913		34,936		5,347		(585)
Net income (loss)		(53,628)		(988,043)		375,746		236,842		(255,530)		214,565		(438,267)		(340,530)

Basic income (loss) per common share:
Net income (loss) per share	$	-	$	(0.04)	$	0.01	$	0.01	$	(0.01)	$	0.01	$	(0.02)	$	(0.01)
Basic weighted average common shares outstanding		28,092,945		27,052,445		26,981,813		26,929,314		26,816,550		26,718,171		26,576,054		26,512,195

Diluted income (loss) per common share:
Net income (loss) per share	$	-	$	(0.04)	$	0.01	$	0.01	$	(0.01)	$	0.01	$	(0.02)	$	(0.01)
Diluted weighted average common shares outstanding		28,092,945		27,052,445		30,058,791		29,791,719		26,815,550		27,779,841		26,576,054		26,512,195

Table of Contents

Comparison of the Three and Six Months Ended December 31, 2023 and 2022

Results of Operations


	Three Months Ended December 31,
	2023		2022		$ Change		% Change

Revenue:
Platforms	$	3,125,584	$	2,110,272	$	1,015,312	48.1	%
Transactions		7,188,158		6,606,394		581,764	8.8	%
Total revenue		10,313,742		8,716,666		1,597,076	18.3	%

Cost of revenue:
Platforms		486,185		253,073		233,112	92.1	%
Transactions		5,343,755		5,059,766		283,989	5.6	%
Total cost of revenue		5,829,940		5,312,839		517,101	9.7	%

Gross profit:
Platforms		2,639,399		1,857,199		782,200	42.1	%
Transactions		1,844,403		1,546,628		297,775	19.3	%
Total gross profit		4,483,802		3,403,827		1,079,975	31.7	%

Operating expenses:
Sales and marketing		804,927		666,608		138,319	20.7	%
Technology and product development		1,336,558		922,132		414,426	44.9	%
General and administrative		2,023,848		1,613,664		410,184	25.4	%
Depreciation and amortization		155,749		6,342		149,407	2,355.8	%
Stock-based compensation expense		596,455		608,703		(12,248)	(2.0)	%
Foreign currency transaction gain		(13,738)		(84,179)		70,441	83.7	%
Total operating expenses		4,903,799		3,733,270		1,170,529	31.4	%

Loss from operations		(419,997)		(329,443)		(90,554)	(27.5)	%

Other income		376,426		74,695		301,731	404.0	%

Loss from operations before provision for income taxes		(43,571)		(254,748)		211,177	82.9	%
Provision for income taxes		(10,057)		(782)		(9,275)	(1,186.1)	%

Net loss	$	(53,628)	$	(255,530)		201,902	79.0	%

Table of Contents


	Six Months Ended December 31,
	2023		2022		$ Change		% Change

Revenue:
Platforms	$	5,725,776	$	4,130,239	$	1,595,537	38.6	%
Transactions		14,648,937		13,271,070		1,377,867	10.4	%
Total revenue		20,374,713		17,401,309		2,973,404	17.1	%

Cost of revenue:
Platforms		868,799		483,546		385,253	79.7	%
Transactions		10,990,546		10,164,688		825,858	8.1	%
Total cost of revenue		11,859,345		10,648,234		1,211,111	11.4	%

Gross profit:
Platforms		4,856,977		3,646,693		1,210,284	33.2	%
Transactions		3,658,391		3,106,382		552,009	17.8	%
Total gross profit		8,515,368		6,753,075		1,762,293	26.1	%

Operating expenses:
Sales and marketing		1,489,943		1,187,824		302,119	25.4	%
Technology and product development		2,581,137		1,797,422		783,715	43.6	%
General and administrative		4,566,717		3,133,088		1,433,629	45.8	%
Depreciation and amortization		215,369		12,154		203,215	1,672.0	%
Stock-based compensation expense		1,188,269		784,064		404,205	51.6	%
Foreign currency transaction gain		(7,118)		(11,663)		4,545	39.0	%
Total operating expenses		10,034,317		6,902,889		3,131,428	45.4	%

Loss from operations		(1,518,949)		(149,814)		(1,369,135)	913.9	%

Other income		516,737		113,764		402,973	354.2	%

Loss from operations before provision for income taxes		(1,002,212)		(36,050)		(966,162)	(2,680.1)	%
Provision for income taxes		(39,459)		(4,915)		(34,544)	(702.8)	%

Net loss	$	(1,041,671)	$	(40,965)		(1,000,706)	(2,442.8)	%

Revenue


	Three Months Ended December 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	3,125,584	$	2,110,272	$	1,015,312	48.1	%
Transactions		7,188,158		6,606,394		581,764	8.8	%
Total revenue	$	10,313,742	$	8,716,666	$	1,597,076	18.3	%

Table of Contents

Total revenue increased $1,597,076, or 18.3%, for the three months ended December 31, 2023 compared to the prior year, due to the following:


Category	Impact			Key Drivers
Platforms	↑	$	1,015,312	Increased due to additional deployments to new and existing customers, expansion from existing customers and additional revenue from the ResoluteAI and Scite transactions. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year for commercial customers and monthly for individual subscribers, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	581,764	Increased primarily due to organic higher paid order volume and additional paid order volume due to the FIZ asset acquisition.


	Six Months Ended December 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	5,725,776	$	4,130,239	$	1,595,537	38.6	%
Transactions		14,648,937		13,271,070		1,377,867	10.4	%
Total revenue	$	20,374,713	$	17,401,309	$	2,973,404	17.1	%

Total revenue increased $2,973,404, or 17.1%, for the six months ended December 31, 2023 compared to the prior year, due to the following:


Category	Impact			Key Drivers
Platforms	↑	$	1,595,537	Increased due to additional deployments to new and existing customers, expansion from existing customers and additional revenue from the ResoluteAI and Scite transactions. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year for commercial customers and monthly for individual subscribers, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	1,377,867	Increased primarily due to organic higher paid order volume and additional paid order volume due to the FIZ asset acquisition.

Cost of Revenue


	Three Months Ended December 31,
	2023		2022		$ Change		% Change
Cost of Revenue:
Platforms	$	486,185	$	253,073	$	233,112	92.1	%
Transactions		5,343,755		5,059,766		283,989	5.6	%
Total cost of revenue	$	5,829,940	$	5,312,839	$	517,101	9.7	%


	Three Months Ended
	December 31,
	2023		2022		% Change *
As a percentage of revenue:
Platforms	15.6	%	12.0	%	3.6	%
Transactions	74.3	%	76.6	%	(2.3)	%
Total	56.5	%	61.0	%	(4.5)	%

Table of Contents

*	The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 4.5%, from 61% for the previous year to 56.5%, for the three months ended December 31, 2023.


	Impact as percentage
Category	of revenue			Key Drivers
Platforms	↑	3.3	%	Increased primarily due to proportionally greater hosting costs from ResoluteAI.
Transactions	↓	2.3	%	Decreased primarily due to higher copyright margins.


	Six Months Ended December 31,
	2023		2022		$ Change		% Change
Cost of Revenue:
Platforms	$	868,799	$	483,546	$	385,253	79.7	%
Transactions		10,990,546		10,164,688		825,858	8.1	%
Total cost of revenue	$	11,859,345	$	10,648,234	$	1,211,111	11.4	%


	Six Months Ended
	December 31,
	2023		2022		% Change *
As a percentage of revenue:
Platforms	15.2	%	11.7	%	3.5	%
Transactions	75.0	%	76.6	%	(1.6)	%
Total	58.2	%	61.2	%	(3.0)	%

*	The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 3%, from 61.2% for the previous year to 58.2%, for the six months ended December 31, 2023.


	Impact as percentage
Category	of revenue			Key Drivers
Platforms	↑	3.5	%	Increased primarily due to proportionally greater hosting costs from ResoluteAI.
Transactions	↓	1.6	%	Decreased primarily due to higher copyright margins.

Gross Profit


	Three Months Ended December 31,
	2023		2022		$ Change		% Change
Gross Profit:
Platforms	$	2,639,399	$	1,857,199	$	782,200	42.1	%
Transactions		1,844,403		1,546,628		297,775	19.3	%
Total gross profit	$	4,483,802	$	3,403,827	$	1,079,975	31.7	%


	Three Months Ended
	December 31,
	2023		2022		% Change*
As a percentage of revenue:
Platforms	84.4	%	88.0	%	(3.6)	%
Transactions	25.7	%	23.4	%	2.3	%
Total	43.5	%	39.0	%	4.5	%

*	The difference between current and prior period gross profit as a percentage of revenue

Table of Contents


	Six Months Ended December 31,
	2023		2022		$ Change		% Change
Gross Profit:
Platforms	$	4,856,977	$	3,646,693	$	1,210,284	33.2	%
Transactions		3,658,391		3,106,382		552,009	17.8	%
Total gross profit	$	8,515,368	$	6,753,075	$	1,762,293	26.1	%


	Six Months Ended
	December 31,
	2023		2022		% Change*
As a percentage of revenue:
Platforms	84.8	%	88.3	%	(3.5)	%
Transactions	25.0	%	23.4	%	1.6	%
Total	41.8	%	38.8	%	3.0	%

*	The difference between current and prior period gross profit as a percentage of revenue

Operating Expenses


	Three Months Ended December 31,
	2023		2022		$ Change		% Change
Operating Expenses:
Sales and marketing	$	804,927	$	666,608	$	138,319	20.7	%
Technology and product development		1,336,558		922,132		414,426	44.9	%
General and administrative		2,023,848		1,613,664		410,184	25.4	%
Depreciation and amortization		155,749		6,342		149,407	2,355.8	%
Stock-based compensation expense		596,455		608,703		(12,248)	(2.0)	%
Foreign currency transaction gain		(13,738)		(84,179)		70,441	83.7	%
Total operating expenses	$	4,903,799	$	3,733,270	$	1,170,529	31.4	%


Category	Impact			Key Drivers
Sales and marketing	↑	$	138,319	Increased primarily due to greater personnel costs from the ResoluteAI and Scite transactions, partially offset by lower consulting expenses.
Technology and product development	↑	$	414,426	Increased due to greater software development personnel costs, primarily from the onboarding personnel from ResoluteAI and Scite, but also due to organic growth in personnel cost.
General and administrative	↑	$	410,184	Increased due to greater legal expenses and personnel costs, primarily from the onboarding of Resolute AI and Scite, partially offset by lower travel expenses. Greater legal expenses include proxy-related and acquisition-related costs.


	Six Months Ended December 31,
	2023		2022		$ Change		% Change
Operating Expenses:
Sales and marketing	$	1,489,943	$	1,187,824	$	302,119	25.4	%
Technology and product development		2,581,137		1,797,422		783,715	43.6	%
General and administrative		4,566,717		3,133,088		1,433,629	45.8	%
Depreciation and amortization		215,369		12,154		203,215	1,672.0	%
Stock-based compensation expense		1,188,269		784,064		404,205	51.6	%
Foreign currency transaction gain		(7,118)		(11,663)		4,545	39.0	%
Total operating expenses	$	10,034,317	$	6,902,889	$	3,131,428	45.4	%

Table of Contents


Category	Impact			Key Drivers
Sales and marketing	↑	$	302,119	Increased primarily due to greater personnel costs, including costs from the ResoluteAI and Scite transactions, and marketing discretionary spend partially offset by lower consulting expenses.
Technology and product development	↑	$	783,715	Increased due to greater software development personnel costs, primarily from the onboarding personnel from ResoluteAI and Scite. ,but also due to organic growth in personnel cost.
General and administrative	↑	$	1,433,629	Increased due to greater legal expenses and personnel costs, primarily from the onboarding of Resolute AI and Scite, partially offset by lower travel expenses. Greater legal expenses include proxy-related and acquisition-related costs. Greater personnel costs include separation costs paid to a former officer as result of the resolution of the proxy matter.

Net Income (Loss)


	Three Months Ended December 31,
	2023		2022		$ Change		% Change
Net Income (Loss):
Net income (loss):	$	(53,628)	$	(255,530)	$	201,902	79.0	%

Net loss decreased $255,530 or 79%, for the three months ended December 31, 2023 compared to the prior year, primarily due to gross profit, partially offset by increased operating expenses as described above.


	Six Months Ended December 31,
	2023		2022		$ Change		% Change
Net Income (Loss):
Net income (loss):	$	(1,041,671)	$	(40,965)	$	(1,000,706)	(2,442.8)	%

Net loss increased $1,000,706 or 2,442%, for the six months ended December 31, 2023 compared to the prior year, primarily due to increased operating expenses, partially offset by increased gross profit as described above.

Liquidity and Capital Resources


	Six Months Ended December 31,
	2023		2022
Consolidated Statements of Cash Flow Data:
Net cash provided by (used in) operating activities	$	(426,888)	$	1,023,585
Net cash used in investing activities		(10,079,509)		(316,326)
Net cash used in financing activities		(346,943)		(48,729)

Effect of exchange rate changes		5,666		859
Net increase (decrease) in cash and cash equivalents		(10,847,674)		659,389
Cash and cash equivalents, beginning of period		13,545,333		10,603,175
Cash and cash equivalents, end of period	$	2,697,659	$	11,262,564

Liquidity

As of December 31, 2023, we had cash and cash equivalents of $2,697,659, compared to $13,545,333 as of June 30, 2023, a decrease of $10,847,674. This decrease was primarily due to cash used in investing activities.

Table of Contents

Operating Activities

Net cash used in operating activities was $426,888 for the six months ended December 31, 2023 and resulted primarily from an increase in accounts receivable of $681,502 and an increase in deferred revenue of $241,545, partially offset by a decrease in prepaid royalties of $121,100.

Net cash provided by operating activities was $1,023,585 for the six months ended December 31, 2022 and resulted primarily from a decrease in prepaid royalties of $805,436, an increase in fair value of vested restricted common stock of $482,327 and an increase in deferred revenue of $428,999, partially offset by a decrease in accounts payable and accrued expenses of $974,931.

Investing Activities

Net cash used in investing activities was $10,079,509 for the six months ended December 31, 2023 and resulted primarily from the payment for the Scite acquisition of $7,305,493 and the payment for the ResoluteAI acquisition of $2,718,253.

Net cash used in investing activities was $316,326 for the six months ended December 31, 2022 and resulted primarily from the payment for non-refundable deposit for asset acquisition of $297,450.

Financing Activities

Net cash used in financing activities was $346,943 for the six months ended December 31, 2023 and resulted from the payment of contingent acquisition consideration of $278,195 and the repurchase of common stock of $68,748.

Net cash used in financing activities was $48,729 for the six months ended December 31, 2022 and resulted from the repurchase of common stock of $48,729.

We entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 28, 2024, and is subject to certain financial and performance covenants with which we were in compliance as of December 31, 2023. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and 5.0%. The interest rate on the line of credit was 9.5% as of December 31, 2023. The line of credit was secured by our consolidated assets.

There were no outstanding borrowings under the line as of December 31, 2023 and June 30, 2023, respectively. As of December 31, 2023, there was approximately $2,426,000 of available credit. On March 27, 2023, First Citizens BancShares, Inc. (“FCB”) entered into an agreement with the Federal Deposit Insurance Corporation (FDIC) to purchase all of the assets and liabilities of SVB. We have confirmed that the Loan and Security Agreement remains in effect post this transaction and that, we continue to have access to the revolving line of credit.

SVB Bridge Bank agreed that we can lower our cash balance threshold requirement associated with the SVB LSA, reducing the required balances of its and its subsidiaries’ primary operating and other accounts with SVB, and we continue to evaluate the SVB LSA. We have established additional banking relationships with Bank of America, N.A. and PNC Bank, N.A. At December 31, 2023, we held cash at Bank of America, N.A. of $124,044 and at PNC Bank, N.A. of $136,730.

Subsequent to September 30, 2023, FCB informed us of certain defaults under the SVB LSA resulting from our violation of certain covenants regarding retaining operating cash with SVB, obtaining deposit account control agreements with respect to such accounts and failing to maintain the required adjusted quick ratio. We became aware of additional technical defaults following FCB’s outreach, and such defaults substantially related to our moves to promptly diversify its cash position following the collapse of Silicon Valley Bank in March of 2023. On November 14, 2023, we entered into a

Table of Contents

Fifth Amendment to Amended and Restated Loan and Security Agreement, Consent and Forbearance Agreement (the “Fifth Amendment”) with FCB, pursuant to which, among other matters, FCB agreed to forbear from exercising its remedies under the SVB LSA in connection with the existing events of default, and agreed to waive the existing events of default provided we regain compliance with the adjusted quick ratio covenant and the operating accounts covenants by January 30, 2024, no other events of defaults have occurred and no forbearance termination events (as listed in the Fifth Amendment) have occurred.

Non-GAAP Measure – Adjusted EBITDA

In addition to our GAAP results, we present Adjusted EBITDA as a supplemental measure of our performance. However, Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of liquidity. We define Adjusted EBITDA as net income (loss), plus interest expense, other income (expense), foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, income from discontinued operations and gain on sale of discontinued operations. Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three and six months ended December 31, 2023 and 2022:


	Three Months Ended
	December 31,
	2023		2022		$ Change
Net income (loss)	$	(53,628)	$	(255,530)	$	201,902
Add (deduct):
Other (income) expense		(376,426)		(74,695)		(301,731)
Foreign currency transaction loss (gain)		(13,738)		(84,179)		70,441
Provision for income taxes		10,057		782		9,275
Depreciation and amortization		155,749		6,342		149,407
Stock-based compensation		596,455		608,703		(12,248)
Adjusted EBITDA	$	318,469	$	201,423	$	117,046


	Six Months Ended
	December 31,
	2023		2022		$ Change
Net income (loss)	$	(1,041,671)	$	(40,965)	$	(1,000,706)
Add (deduct):
Other (income) expense		(516,737)		(113,764)		(402,973)
Foreign currency transaction loss (gain)		(7,118)		(11,663)		4,545
Provision for income taxes		39,459		4,915		34,544
Depreciation and amortization		215,369		12,154		203,215
Stock-based compensation		1,188,269		784,064		404,205
Adjusted EBITDA	$	(122,429)	$	634,741	$	(757,170)

We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; and in making compensation

Table of Contents

decisions and in communications with our board of directors concerning our financial performance. Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following:

●

Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

●

Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

●

Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and

●

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2023, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.

Inherent Limitations on the Effectiveness of Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

Table of Contents

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control Over Financial Reporting

In addition, our management with the participation of our principal executive officer and principal financial officer have determined that no change in our internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Exchange Act) occurred during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1A. Risk Factors.

There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended December 31, 2023, we repurchased 8,501 shares of our common stock from employees at an average market price of approximately $2.66 per share for an aggregate amount of $22,613. As of December 31, 2023, $82,347 remains under the current authorization to repurchase our outstanding common stock from our employees.

Table of Contents

The following table summarizes repurchases of our common stock on a monthly basis:


				Total Number of Shares	Approximate Dollar Value
	Total Number	Average		Purchased as Part of	of Shares that May Yet Be
	of Shares	Price Paid		Publicly Announced	Purchased Under the
Period	Purchased¹	per Share		Plans or Programs	Plans or Programs
October 1-31, 2023	—		—	—	$	104,960
November 1-30, 2023	—		—	—	$	104,960
December 1-31, 2023	8,501	$	2.66	—	$	82,347
Total	8,501	$	2.66	—		—

¹ Consists of shares of common stock purchased from an employee to satisfy tax obligations in connection with the vesting of stock incentive awards.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit Number	Description
2.1	Agreement and Plan of Merger by and among Reprints Desk, Inc., Research Solutions Acquisition Corp 1, Research Solutions, Inc., as Parent Guarantor, Resolute Innovation, Inc. and Shareholder Representative Services LLC dated as of July 28, 2023. (Incorporated by reference to Exhibit 2.1 to the registrant’s Current Report on Form 8-K filed on July 31, 2023.)
2.2	Agreement of Merger and Plan of Reorganization, by and among the Research Solutions, Inc., Research Solutions Acquisition 2, LLC, Scite, Inc., and the Stockholder Representative, dated as of November 24, 2023. (Incorporated by reference to Exhibit 2.1 to the registrant’s Current Report on Form 8-K filed on November 24, 2023.)
3.1.1	Articles of Incorporation. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form SB-2 filed on December 28, 2007.)
3.1.2	Articles of Merger Effective March 4, 2013. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on March 6, 2013.)
3.2	Amended and Restated Bylaws. (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on October 17, 2012.)
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer *
32.2	Section 1350 Certification of Chief Financial Officer *
101.INS	INLINE XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

* Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	RESEARCH SOLUTIONS, INC.

	By:	/s/ Roy W. Olivier
		Roy W. Olivier
Date: February 12, 2024		Chief Executive Officer and President (Principal Executive Officer)

	By:	/s/ William Nurthen
		William Nurthen
Date: February 12, 2024		Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION

I, Roy W. Olivier, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: February 12, 2024		/s/ Roy W. Olivier
		Roy W. Olivier
		Chief Executive Officer and President (Principal Executive Officer)

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION

I, William Nurthen, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: February 12, 2024		/s/ William Nurthen
		William Nurthen
		Chief Financial Officer (Principal Financial and
		Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roy W. Olivier, Chief Executive Officer and President, and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Roy W. Olivier
Roy W. Olivier
Chief Executive Officer and President (Principal Executive Officer)
February 12, 2024

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William Nurthen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ William Nurthen
William Nurthen
Chief Financial Officer (Principal Financial and Accounting Officer)
February 12, 2024

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2023	Feb. 05, 2024
Document And Entity Information
Document Type	10-Q
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Entity File Number	001-39256
Entity Registrant Name	RESEARCH SOLUTIONS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	11-3797644
Entity Address, Address Line One	Address not applicable1
Entity Address, City or Town	N/A
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	N/A
City Area Code	310
Local Phone Number	477-0354
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	RSSS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,620,507
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001386301
Amendment Flag	false
Document Quarterly Report	true

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,697,659	$ 13,545,333
Accounts receivable, net of allowance of $94,991 and $85,015, respectively	7,289,248	6,153,063
Prepaid expenses and other current assets	547,786	400,340
Prepaid royalties	1,081,578	1,202,678
Total current assets	11,616,271	21,301,414
Goodwill (provisional)	16,451,937	0
Other assets:
Property and equipment, net of accumulated depreciation of $905,411 and $881,908, respectively	103,195	70,193
Intangible assets, net of accumulated amortization of $940,234 and $747,355, respectively ($10,806,487 provisional)	11,290,225	462,068
Deposits and other assets	1,060	1,052
Total assets	39,462,688	21,834,727
Current liabilities:
Accounts payable and accrued expenses	8,862,829	8,079,516
Deferred revenue	7,843,674	6,424,724
Total current liabilities	16,706,503	14,504,240
Long-term liabilities:
Contingent earnout liability	8,792,811	0
Total liabilities	25,499,314	14,504,240
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,619,598 and 29,487,508 shares issued and outstanding, respectively	32,620	29,487
Additional paid-in capital	37,607,895	29,941,873
Accumulated deficit	(23,564,320)	(22,522,649)
Accumulated other comprehensive loss	(112,821)	(118,224)
Total stockholders' equity	13,963,374	7,330,487
Total liabilities and stockholders' equity	$ 39,462,688	$ 21,834,727

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Condensed Consolidated Balance Sheets
Net of allowance	$ 94,991	$ 85,015
Property and equipment, net of accumulated depreciation	905,411	881,908
Intangible assets, net of accumulated amortization	940,234	$ 747,355
Intangible assets, provisional	$ 10,806,487
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	32,619,598	29,487,508
Common stock, shares, outstanding	32,619,598	29,487,508

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 10,313,742	$ 8,716,666	$ 20,374,713	$ 17,401,309
Cost of revenue:
Total cost of revenue	5,829,940	5,312,839	11,859,345	10,648,234
Gross profit	4,483,802	3,403,827	8,515,368	6,753,075
Operating expenses:
Selling, general and administrative	4,748,050	3,726,928	9,818,948	6,890,735
Depreciation and amortization	155,749	6,342	215,369	12,154
Total operating expenses	4,903,799	3,733,270	10,034,317	6,902,889
Loss from operations	(419,997)	(329,443)	(1,518,949)	(149,814)
Other income	376,426	74,695	516,737	113,764
Loss from operations before provision for income taxes	(43,571)	(254,748)	(1,002,212)	(36,050)
Provision for income taxes	(10,057)	(782)	(39,459)	(4,915)
Net loss	(53,628)	(255,530)	(1,041,671)	(40,965)
Other comprehensive income (loss):
Foreign currency translation	6,349	6,524	5,403	1,348
Comprehensive loss	$ (47,279)	$ (249,006)	$ (1,036,268)	$ (39,617)
Loss per common share:
Net loss per share, basic	$ 0	$ (0.01)	$ (0.04)	$ 0
Net loss per share, diluted	$ 0.00	$ (0.01)	$ (0.04)
Weighted average common shares outstanding, basic	28,092,945	26,816,550	27,564,404	26,767,360
Weighted average common shares outstanding, diluted	28,092,945	26,816,550	27,564,404	26,767,360
Platforms
Revenue:
Total revenue	$ 3,125,584	$ 2,110,272	$ 5,725,776	$ 4,130,239
Cost of revenue:
Total cost of revenue	486,185	253,073	868,799	483,546
Transactions
Revenue:
Total revenue	7,188,158	6,606,394	14,648,937	13,271,070
Cost of revenue:
Total cost of revenue	$ 5,343,755	$ 5,059,766	$ 10,990,546	$ 10,164,688

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Total
Balance at Jun. 30, 2022	$ 27,076	$ 28,072,855	$ (23,094,272)	$ (121,941)	$ 4,883,718
Balance (in shares) at Jun. 30, 2022	27,075,648
Fair value of vested stock options		301,737			301,737
Fair value of vested restricted common stock	$ 2,022	480,305			482,327
Fair value of vested restricted common stock (in shares)	2,022,334
Repurchase of common stock	$ (25)	(48,704)			(48,729)
Repurchase of common stock (in shares)	(25,800)
Fair value of vested unrestricted common stock	$ 36	68,236			68,272
Fair value of vested unrestricted common stock (in shares)	36,509
Common stock issued upon exercise of stock options	$ 46	(46)
Common stock issued upon exercise of stock options (in shares)	46,046
Net income (loss) for the period			(40,965)		(40,965)
Foreign currency translation				1,348	1,348
Balance at Dec. 31, 2022	$ 29,155	28,874,383	(23,135,237)	(120,593)	5,647,708
Balance (in shares) at Dec. 31, 2022	29,154,737
Balance at Jun. 30, 2022	$ 27,076	28,072,855	(23,094,272)	(121,941)	4,883,718
Balance (in shares) at Jun. 30, 2022	27,075,648
Balance at Jun. 30, 2023	$ 29,487	29,941,873	(22,522,649)	(118,224)	7,330,487
Balance (in shares) at Jun. 30, 2023	29,487,508
Balance at Sep. 30, 2022	$ 27,331	28,298,171	(22,879,707)	(127,117)	5,318,678
Balance (in shares) at Sep. 30, 2022	27,330,878
Fair value of vested stock options		261,031			261,031
Fair value of vested restricted common stock	$ 1,800	345,872			347,672
Fair value of vested restricted common stock (in shares)	1,800,000
Repurchase of common stock	$ (16)	(30,651)			(30,667)
Repurchase of common stock (in shares)	(16,141)
Common stock issued upon exercise of stock options	$ 40	(40)
Common stock issued upon exercise of stock options (in shares)	40,000
Net income (loss) for the period			(255,530)		(255,530)
Foreign currency translation				6,524	6,524
Balance at Dec. 31, 2022	$ 29,155	28,874,383	(23,135,237)	(120,593)	5,647,708
Balance (in shares) at Dec. 31, 2022	29,154,737
Balance at Jun. 30, 2023	$ 29,487	29,941,873	(22,522,649)	(118,224)	7,330,487
Balance (in shares) at Jun. 30, 2023	29,487,508
Fair value of vested stock options		61,714			61,714
Fair value of vested restricted common stock	$ 380	1,105,226			1,105,606
Fair value of vested restricted common stock (in shares)	380,000
Repurchase of common stock	$ (27)	(68,721)			$ (68,748)
Repurchase of common stock (in shares)	(27,104)
Common stock issued upon exercise of stock options	$ 51	(51)
Common stock issued upon exercise of stock options (in shares)	50,180				319,550
Common stock issued for acquisition of Scite	$ 2,729	6,546,905			$ 6,549,634
Common stock issued for acquisition of Scite (in shares)	2,729,014
Modification cost of stock options		20,949			20,949
Net income (loss) for the period			(1,041,671)		(1,041,671)
Foreign currency translation				5,403	5,403
Balance at Dec. 31, 2023	$ 32,620	37,607,895	(23,564,320)	(112,821)	13,963,374
Balance (in shares) at Dec. 31, 2023	32,619,598
Balance at Sep. 30, 2023	$ 29,624	30,487,415	(23,510,692)	(119,170)	6,887,177
Balance (in shares) at Sep. 30, 2023	29,624,085
Fair value of vested stock options		44,243			44,243
Fair value of vested restricted common stock	$ 275	530,988			531,263
Fair value of vested restricted common stock (in shares)	275,000
Repurchase of common stock	$ (8)	(22,605)			(22,613)
Repurchase of common stock (in shares)	(8,501)
Common stock issued for acquisition of Scite	$ 2,729	6,546,905			6,549,634
Common stock issued for acquisition of Scite (in shares)	2,729,014
Modification cost of stock options		20,949			20,949
Net income (loss) for the period			(53,628)		(53,628)
Foreign currency translation				6,349	6,349
Balance at Dec. 31, 2023	$ 32,620	$ 37,607,895	$ (23,564,320)	$ (112,821)	$ 13,963,374
Balance (in shares) at Dec. 31, 2023	32,619,598

Condensed Consolidated Statements of Cash Flows	6 Months Ended
Condensed Consolidated Statements of Cash Flows	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Cash flow from operating activities:
Net income (loss)	$ (1,041,671)	$ (40,965)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	215,369	12,154
Fair value of vested stock options	61,714	301,737
Fair value of vested restricted common stock	1,105,606	482,327
Fair value of vested unrestricted common stock	0	68,272
Modification cost of accelerated vesting of restricted common stock	20,949	0
Changes in operating assets and liabilities:
Accounts receivable	(681,502)	8,159
Prepaid expenses and other current assets	(67,986)	(67,603)
Prepaid royalties	121,100	805,436
Accounts payable and accrued expenses	81,078	(974,931)
Deferred revenue	(241,545)	428,999
Net cash provided by (used in) operating activities	(426,888)	1,023,585
Cash flow from investing activities:
Purchase of property and equipment	(55,763)	(18,876)
Payment for non-refundable deposit for asset acquisition	0	(297,450)
Net cash used in investing activities	(10,079,509)	(316,326)
Cash flow from financing activities:
Common stock repurchase	(68,748)	(48,729)
Payment of contingent acquisition consideration	(278,195)	0
Net cash used in financing activities	(346,943)	(48,729)
Effect of exchange rate changes	5,666	859
Net decrease in cash and cash equivalents	(10,847,674)	659,389
Cash and cash equivalents, beginning of period	13,545,333	10,603,175
Cash and cash equivalents, end of period	2,697,659	11,262,564
Supplemental disclosures of cash flow information:
Cash paid for income taxes	39,459	4,915
Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	36,364	0
Resolute
Cash flow from investing activities:
Payment for acquisition, net of cash acquired	(2,718,253)	0
Scite
Cash flow from investing activities:
Payment for acquisition, net of cash acquired	$ (7,305,493)	$ 0

Organization, Nature of Business and Basis of Presentation

6 Months Ended

Dec. 31, 2023

Organization, Nature of Business and Basis of Presentation

Organization, Nature of Business and Basis of Presentation

Note 1. Organization, Nature of Business and Basis of Presentation

Organization

Nature of Business

Platforms

Transactions

Principles of Consolidation

Basis of Presentation

Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Use of Estimates

Concentration of Credit Risk

The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at December 31, 2023 and June 30, 2023.

The following table summarizes vendor concentrations:


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2023		2022		2023		2022
Vendor A	26	%	21	%	25	%	21	%
Vendor B	10	%	13	%	11	%	12	%

Revenue Recognition

features of our cloud-based SaaS research intelligence platforms (Platforms) and the transactional sale of STM content managed, sourced and delivered through the Platform (Transactions).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	December 31,
	2023				2022
United States	$	6,070,189	58.9	%	$	5,061,779	58.1	%
Europe		3,301,660	32.0	%		2,963,155	34.0	%
Rest of World		941,893	9.1	%		691,732	7.9	%
Total	$	10,313,742	100	%	$	8,716,666	100	%


	Six Months Ended
	December 31,
	2023				2022
United States	$	11,931,113	58.6	%	$	10,104,860	58.1	%
Europe		6,457,252	31.7	%		5,972,746	34.3	%
Rest of World		1,986,348	9.7	%		1,323,703	7.6	%
Total	$	20,374,713	100	%	$	17,401,309	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of December 31, 2023				As of June 30, 2023
United States	$	3,989,404	54.7	%	$	3,727,977	60.6	%
Europe		2,317,166	31.8	%		1,763,044	28.7	%
Rest of World		982,678	13.5	%		662,042	10.8	%
Total	$	7,289,248	100	%	$	6,153,063	100	%

Business Combinations

Intangible Assets

Goodwill

Deferred Revenue

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Stock-Based Compensation

Foreign Currency

The following table summarizes the exchange rates used:


	Six Months Ended		Year Ended
	December 31,		June 30,
	2023	2022	2023	2022
Period end Euro : US Dollar exchange rate	1.10	1.07	1.09	1.05
Average period Euro : US Dollar exchange rate	1.08	1.01	1.05	1.13

Period end GBP : US Dollar exchange rate	1.27	1.21	1.27	1.21
Average period GBP : US Dollar exchange rate	1.25	1.17	1.20	1.34

Period end Mexican Peso : US Dollar exchange rate	0.06	0.05	0.06	0.05
Average period Mexican Peso : US Dollar exchange rate	0.06	0.05	0.05	0.05

Net Income (Loss) Per Share

Recently Issued Accounting Pronouncements

Line of Credit

6 Months Ended

Dec. 31, 2023

Line of Credit

Line of Credit

Note 3. Line of Credit

5.0%. The interest rate on the line of credit was 9.5% as of December 31, 2023. The line of credit is secured by the Company’s consolidated assets.

Stockholders' Equity

6 Months Ended

Dec. 31, 2023

Stockholders' Equity

Stockholders' Equity

Note 4. Stockholders’ Equity

Stock Options

under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The following table summarizes vested and unvested stock option activity:


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2023	2,909,574	$	1.87	2,865,593	$	1.86	43,981	$	2.47
Granted	257,934		2.73	—		—	257,934		2.73
Options vesting	—		—	26,137		2.44	(26,137)		2.44
Exercised	(319,550)		2.03	(319,550)		2.03	—		—
Forfeited	—		—	—		—	—		—
Outstanding at December 31, 2023	2,847,958	$	1.93	2,572,180	$	1.84	275,778	$	2.72

The following table presents the information regarding stock options outstanding and exercisable as of December 31, 2023:


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.93	225,000
	0.77	25,000	0.63	25,000
	0.80	16,000	1.64	16,000
	0.90	15,000	1.59	15,000
	1.00	15,000	1.19	15,000
	1.05	305,000	2.65	305,000
	1.09	40,000	2.40	40,000
	1.10	105,000	1.50	105,000
	1.20	274,000	3.55	274,000
	1.59	25,000	4.36	25,000
	2.10	238,767	8.11	238,767
	2.13	216,708	6.88	216,708
	2.15	200,000	8.95	200,000
	2.17	35,955	7.36	32,958
	2.19	5,000	8.05	3,333
	2.40	302,833	4.87	302,833
	2.43	61,250	7.43	58,750
	2.45	98,000	6.59	98,000
	2.49	78,435	6.42	78,435
	2.50	20,000	5.38	20,000
	2.64	30,882	7.60	25,734
	2.67	33,194	7.72	27,662
	2.73	257,934	9.94	—
	2.99	8,000	6.37	8,000
	3.13	208,000	5.87	208,000
	3.50	8,000	6.12	8,000
	Total	2,847,958		2,572,180

Restricted Common Stock

•20% at a 30-day VWAP of $3.00 per share;

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

The following table summarizes restricted common stock activity:


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2023	2,477,794	$	2,711,661	$	1.52
Granted	380,000		860,650		2.26
Vested	(178,570)		(1,126,555)		2.08
Forfeited	—		—		—
Non-vested, December 31, 2023	2,679,224	$	2,445,756	$	1.59

Common Stock Repurchases

Acquisitions

6 Months Ended

Dec. 31, 2023

Acquisitions

Acquisition

Note 5. Acquisitions

FIZ

ResoluteAI

Scite


	Pro Forma (Unaudited)				Pro Forma (Unaudited)
	Three Months ended December 31,				Six Months ended December 31,
	2023		2022		2023		2022

Revenue	$	11,033,441	$	8,793,998	$	21,834,349	$	17,663,493
Cost of revenue		5,877,494		5,363,807		11,967,550		10,742,750
Gross profit		5,155,947		3,430,191		9,866,799		6,920,743

Total operating expenses		5,524,052		4,031,029		11,197,427		7,461,089

Loss from operations		(368,105)		(600,838)		(1,330,628)		(540,346)

Other income		376,426		74,695		516,737		113,764

Income (loss) from operations before provision for income taxes		8,321		(526,143)		(813,891)		(426,582)
Provision for income taxes		(10,057)		(782)		(39,459)		(4,915)

Pro Forma Net loss	$	(1,736)	$	(526,925)	$	(853,350)	$	(431,497)
Pro Forma Net loss per weighted average share, basic and diluted	$	-	$	(0.02)	$	(0.03)	$	(0.02)

Contingencies

6 Months Ended

Dec. 31, 2023

Contingencies

Contingencies

Note 6. Contingencies

Inflation Risk

Subsequent Events

6 Months Ended

Dec. 31, 2023

Subsequent Events

Subsequent Events

Note 7. Subsequent Events

On January 5, 2024, the Company issued 909 net shares of common stock upon the exercise of stock options underlying 7,500 shares of common stock on a cashless basis.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Dec. 31, 2023

Summary of Significant Accounting Policies

Use of Estimates

Concentration of Credit Risk

The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at December 31, 2023 and June 30, 2023.

The following table summarizes vendor concentrations:


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2023		2022		2023		2022
Vendor A	26	%	21	%	25	%	21	%
Vendor B	10	%	13	%	11	%	12	%

Revenue Recognition

features of our cloud-based SaaS research intelligence platforms (Platforms) and the transactional sale of STM content managed, sourced and delivered through the Platform (Transactions).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	December 31,
	2023				2022
United States	$	6,070,189	58.9	%	$	5,061,779	58.1	%
Europe		3,301,660	32.0	%		2,963,155	34.0	%
Rest of World		941,893	9.1	%		691,732	7.9	%
Total	$	10,313,742	100	%	$	8,716,666	100	%


	Six Months Ended
	December 31,
	2023				2022
United States	$	11,931,113	58.6	%	$	10,104,860	58.1	%
Europe		6,457,252	31.7	%		5,972,746	34.3	%
Rest of World		1,986,348	9.7	%		1,323,703	7.6	%
Total	$	20,374,713	100	%	$	17,401,309	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of December 31, 2023				As of June 30, 2023
United States	$	3,989,404	54.7	%	$	3,727,977	60.6	%
Europe		2,317,166	31.8	%		1,763,044	28.7	%
Rest of World		982,678	13.5	%		662,042	10.8	%
Total	$	7,289,248	100	%	$	6,153,063	100	%

Business Combinations

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Stock-Based Compensation

Foreign Currency

The following table summarizes the exchange rates used:


	Six Months Ended		Year Ended
	December 31,		June 30,
	2023	2022	2023	2022
Period end Euro : US Dollar exchange rate	1.10	1.07	1.09	1.05
Average period Euro : US Dollar exchange rate	1.08	1.01	1.05	1.13

Period end GBP : US Dollar exchange rate	1.27	1.21	1.27	1.21
Average period GBP : US Dollar exchange rate	1.25	1.17	1.20	1.34

Period end Mexican Peso : US Dollar exchange rate	0.06	0.05	0.06	0.05
Average period Mexican Peso : US Dollar exchange rate	0.06	0.05	0.05	0.05

Net Income (Loss) Per Share

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2023

Summary of Significant Accounting Policies

Schedule of vendor concentration risk percentage


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2023		2022		2023		2022
Vendor A	26	%	21	%	25	%	21	%
Vendor B	10	%	13	%	11	%	12	%

Schedule of revenue by geographical region


	Three Months Ended
	December 31,
	2023				2022
United States	$	6,070,189	58.9	%	$	5,061,779	58.1	%
Europe		3,301,660	32.0	%		2,963,155	34.0	%
Rest of World		941,893	9.1	%		691,732	7.9	%
Total	$	10,313,742	100	%	$	8,716,666	100	%


	Six Months Ended
	December 31,
	2023				2022
United States	$	11,931,113	58.6	%	$	10,104,860	58.1	%
Europe		6,457,252	31.7	%		5,972,746	34.3	%
Rest of World		1,986,348	9.7	%		1,323,703	7.6	%
Total	$	20,374,713	100	%	$	17,401,309	100	%

Schedule of accounts receivable by geographical region


	As of December 31, 2023				As of June 30, 2023
United States	$	3,989,404	54.7	%	$	3,727,977	60.6	%
Europe		2,317,166	31.8	%		1,763,044	28.7	%
Rest of World		982,678	13.5	%		662,042	10.8	%
Total	$	7,289,248	100	%	$	6,153,063	100	%

Schedule of foreign currency exchange rate

The following table summarizes the exchange rates used:


	Six Months Ended		Year Ended
	December 31,		June 30,
	2023	2022	2023	2022
Period end Euro : US Dollar exchange rate	1.10	1.07	1.09	1.05
Average period Euro : US Dollar exchange rate	1.08	1.01	1.05	1.13

Period end GBP : US Dollar exchange rate	1.27	1.21	1.27	1.21
Average period GBP : US Dollar exchange rate	1.25	1.17	1.20	1.34

Period end Mexican Peso : US Dollar exchange rate	0.06	0.05	0.06	0.05
Average period Mexican Peso : US Dollar exchange rate	0.06	0.05	0.05	0.05

Stockholders' Equity (Tables)

6 Months Ended

Dec. 31, 2023

Stockholders' Equity

Schedule of vested and unvested stock option activity

The following table summarizes vested and unvested stock option activity:


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2023	2,909,574	$	1.87	2,865,593	$	1.86	43,981	$	2.47
Granted	257,934		2.73	—		—	257,934		2.73
Options vesting	—		—	26,137		2.44	(26,137)		2.44
Exercised	(319,550)		2.03	(319,550)		2.03	—		—
Forfeited	—		—	—		—	—		—
Outstanding at December 31, 2023	2,847,958	$	1.93	2,572,180	$	1.84	275,778	$	2.72

Schedule of additional information regarding stock options outstanding and exercisable


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.93	225,000
	0.77	25,000	0.63	25,000
	0.80	16,000	1.64	16,000
	0.90	15,000	1.59	15,000
	1.00	15,000	1.19	15,000
	1.05	305,000	2.65	305,000
	1.09	40,000	2.40	40,000
	1.10	105,000	1.50	105,000
	1.20	274,000	3.55	274,000
	1.59	25,000	4.36	25,000
	2.10	238,767	8.11	238,767
	2.13	216,708	6.88	216,708
	2.15	200,000	8.95	200,000
	2.17	35,955	7.36	32,958
	2.19	5,000	8.05	3,333
	2.40	302,833	4.87	302,833
	2.43	61,250	7.43	58,750
	2.45	98,000	6.59	98,000
	2.49	78,435	6.42	78,435
	2.50	20,000	5.38	20,000
	2.64	30,882	7.60	25,734
	2.67	33,194	7.72	27,662
	2.73	257,934	9.94	—
	2.99	8,000	6.37	8,000
	3.13	208,000	5.87	208,000
	3.50	8,000	6.12	8,000
	Total	2,847,958		2,572,180

Schedule of restricted common stock activity

The following table summarizes restricted common stock activity:


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2023	2,477,794	$	2,711,661	$	1.52
Granted	380,000		860,650		2.26
Vested	(178,570)		(1,126,555)		2.08
Forfeited	—		—		—
Non-vested, December 31, 2023	2,679,224	$	2,445,756	$	1.59

Acquisitions (Tables)

6 Months Ended

Dec. 31, 2023

Acquisitions

Schedule of pro forma operating results


	Pro Forma (Unaudited)				Pro Forma (Unaudited)
	Three Months ended December 31,				Six Months ended December 31,
	2023		2022		2023		2022

Revenue	$	11,033,441	$	8,793,998	$	21,834,349	$	17,663,493
Cost of revenue		5,877,494		5,363,807		11,967,550		10,742,750
Gross profit		5,155,947		3,430,191		9,866,799		6,920,743

Total operating expenses		5,524,052		4,031,029		11,197,427		7,461,089

Loss from operations		(368,105)		(600,838)		(1,330,628)		(540,346)

Other income		376,426		74,695		516,737		113,764

Income (loss) from operations before provision for income taxes		8,321		(526,143)		(813,891)		(426,582)
Provision for income taxes		(10,057)		(782)		(39,459)		(4,915)

Pro Forma Net loss	$	(1,736)	$	(526,925)	$	(853,350)	$	(431,497)
Pro Forma Net loss per weighted average share, basic and diluted	$	-	$	(0.02)	$	(0.03)	$	(0.02)

Organization, Nature of Business and Basis of Presentation (Details)	6 Months Ended
	Dec. 31, 2023 item subsidiary
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of subsidiaries \| subsidiary	5
Number of service offerings	2
Number of existing STM articles on the platform	100,000,000
Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of newly published STM articles each year.	2,000,000
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of newly published STM articles each year.	4,000,000

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2023 USD ($) item	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) item shares	Dec. 31, 2022 USD ($) shares	Jun. 30, 2023 USD ($)
FDIC insured amount	$ 250,000		$ 250,000
Cash and cash equivalents	2,697,659		$ 2,697,659		$ 13,545,333
Antidilutive securities amount \| shares			2,679,224
Foreign currency transaction gain (loss)	$ 13,738	$ 84,179	$ 7,118	$ 11,663
Number of revenue streams \| item	2		2
Estimated average useful life			10 years
Employee stock options
Antidilutive securities amount \| shares			2,847,958	3,070,224
Restricted Common Stock
Antidilutive securities amount \| shares			2,679,224	2,300,283
Maximum \| Scite
Estimated average useful life			10 years
Maximum \| Developed Technology and Customer Relationships [Member] \| Scite
Estimated average useful life			10 years
Minimum \| Scite
Estimated average useful life			3 years
Minimum \| Developed Technology and Customer Relationships [Member] \| Scite
Estimated average useful life			3 years
Europe financial institutions
Cash and cash equivalents	$ 447,269		$ 447,269		$ 1,760,323

Summary of Significant Accounting Policies - Concentrations (Details) - Content costs from vendors - Supplier Concentration	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Vendor A
Concentration percentage	26.00%	21.00%	25.00%	21.00%
Vendor B
Concentration percentage	10.00%	13.00%	11.00%	12.00%

Summary of Significant Accounting Policies - Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Revenues	$ 10,313,742	$ 8,716,666	$ 20,374,713	$ 17,401,309
Percentage of revenue	100.00%	100.00%	100.00%	100.00%
Accounts receivable
Revenues			$ 7,289,248		$ 6,153,063
Percentage of revenue			100.00%		100.00%
United States
Revenues	$ 6,070,189	$ 5,061,779	$ 11,931,113	$ 10,104,860
Percentage of revenue	58.90%	58.10%	58.60%	58.10%
United States \| Accounts receivable
Revenues			$ 3,989,404		$ 3,727,977
Percentage of revenue			54.70%		60.60%
Europe
Revenues	$ 3,301,660	$ 2,963,155	$ 6,457,252	$ 5,972,746
Percentage of revenue	32.00%	34.00%	31.70%	34.30%
Europe \| Accounts receivable
Revenues			$ 2,317,166		$ 1,763,044
Percentage of revenue			31.80%		28.70%
Rest of World
Revenues	$ 941,893	$ 691,732	$ 1,986,348	$ 1,323,703
Percentage of revenue	9.10%	7.90%	9.70%	7.60%
Rest of World \| Accounts receivable
Revenues			$ 982,678		$ 662,042
Percentage of revenue			13.50%		10.80%

Summary of Significant Accounting Policies - Exchange rates (Details)	6 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Euro to US Dollar
Period end exchange rate	1.10	1.07	1.09	1.05
Average period exchange rate	1.08	1.01	1.05	1.13
GBP To US Dollar
Period end exchange rate	1.27	1.21	1.27	1.21
Average period exchange rate	1.25	1.17	1.20	1.34
Mexican Peso to US Dollar
Period end exchange rate	0.06	0.05	0.06	0.05
Average period exchange rate	0.06	0.05	0.05	0.05

Line of Credit (Details)		6 Months Ended
Line of Credit (Details)	Jul. 23, 2010 USD ($)	Dec. 31, 2023 USD ($)
Line of credit amount	$ 2,500,000
Percentage of eligible accounts receivable	80.00%
Line of credit facility expiration date		Feb. 28, 2024
Covenants ratio		1.15
Fixed interest rate		5.00%
Interest rate on the line of credit		9.50%
Outstanding borrowings under line of credit		$ 0
Approximate available credit		$ 2,426,000
Prime Rate [Member]
Marginal interest rate		1.00%
Bank of America NA [Member]
Cash		$ 124,044
PNC Bank NA [Member]
Cash		$ 136,730

Stockholders' Equity - Options Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Nov. 17, 2021	Nov. 16, 2021	Nov. 17, 2020	Nov. 16, 2020	Nov. 21, 2017	Sep. 30, 2017	Nov. 10, 2016	Nov. 09, 2016
Term number of years			5 years
Weighted average remaining contractual life of all options outstanding			5 years 6 months 10 days
Remaining contractual life for options vested and exercisable			5 years 25 days
Aggregate intrinsic value of options outstanding										$ 2,076,104
Aggregate intrinsic value of options vested and exercisable	$ 2,073,707		$ 2,073,707
Granted (in shares)			257,934
Fair value of stock options granted			$ 340,473
Fair value of vested stock options	44,243	$ 261,031	61,714	$ 301,737
Amount of unvested compensation related to stock options	$ 335,335		$ 335,335
Common stock issued upon exercise of stock options			319,550
Common Stock
Number of shares of restricted common stock issued	275,000	1,800,000	380,000	2,022,334
Common stock issued upon exercise of stock options		40,000	50,180	46,046
Employee stock options
Vesting period			3 years
Number of year(s) cliff vesting period			1 year
Term number of years			10 years
Employee stock options \| 2007 Plan
Number of shares authorized under the plan											7,000,000	5,000,000
Number of shares available for grant	0		0
Employee stock options \| 2017 Plan
Number of shares authorized under the plan									1,874,513
Number of shares available for grant	857,993		857,993
Employee stock options \| Omnibus Incentive 2017 Plan [Member]
Number of shares authorized under the plan					6,874,513	3,374,513	3,374,513	2,374,513

Stockholders' Equity - Stock option Activity (Details)	6 Months Ended
Stockholders' Equity - Stock option Activity (Details)	Dec. 31, 2023 $ / shares shares
Outstanding beginning balance (in shares) \| shares	2,909,574
Granted (in shares) \| shares	257,934
Exercised (in shares) \| shares	(319,550)
Outstanding ending balance (in shares) \| shares	2,847,958
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 1.87
Granted Weighted Average Exercise Price \| $ / shares	2.73
Exercised Weighted Average Exercise Price \| $ / shares	2.03
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 1.93
Vested Options [Member]
Outstanding beginning balance (in shares) \| shares	2,865,593
Options vesting (in shares) \| shares	26,137
Exercised (in shares) \| shares	(319,550)
Outstanding ending balance (in shares) \| shares	2,572,180
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 1.86
Options vesting Weighted Average Exercise Price \| $ / shares	2.44
Exercised Weighted Average Exercise Price \| $ / shares	2.03
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 1.84
Unvested Options [Member]
Outstanding beginning balance (in shares) \| shares	43,981
Granted (in shares) \| shares	257,934
Options vesting (in shares) \| shares	26,137
Outstanding ending balance (in shares) \| shares	275,778
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 2.47
Granted Weighted Average Exercise Price \| $ / shares	2.73
Options vesting Weighted Average Exercise Price \| $ / shares	2.44
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 2.72

Stockholders' Equity - Valuation assumptions (Details)	6 Months Ended
Stockholders' Equity - Valuation assumptions (Details)	Dec. 31, 2023
Minimum
Expected life (in years)	8 months 4 days
Maximum
Expected life (in years)	2 years 6 months 3 days

Stockholders' Equity - Stock options by exercise price (Details)	6 Months Ended
	Dec. 31, 2023 $ / shares shares
Options Outstanding	2,847,958
Options Exercisable	2,572,180
Range One
Option Exercise Price \| $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	1 year 11 months 4 days
Options Exercisable	225,000
Range Two
Option Exercise Price \| $ / shares	$ 0.77
Options Outstanding	25,000
Remaining Contractual Life (in years)	7 months 17 days
Options Exercisable	25,000
Range Three
Option Exercise Price \| $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	1 year 7 months 20 days
Options Exercisable	16,000
Range Four
Option Exercise Price \| $ / shares	$ 0.90
Options Outstanding	15,000
Remaining Contractual Life (in years)	1 year 7 months 2 days
Options Exercisable	15,000
Range Five
Option Exercise Price \| $ / shares	$ 1.00
Options Outstanding	15,000
Remaining Contractual Life (in years)	1 year 2 months 8 days
Options Exercisable	15,000
Range Six
Option Exercise Price \| $ / shares	$ 1.05
Options Outstanding	305,000
Remaining Contractual Life (in years)	2 years 7 months 24 days
Options Exercisable	305,000
Range Seven
Option Exercise Price \| $ / shares	$ 1.09
Options Outstanding	40,000
Remaining Contractual Life (in years)	2 years 4 months 24 days
Options Exercisable	40,000
Range Eight
Option Exercise Price \| $ / shares	$ 1.10
Options Outstanding	105,000
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	105,000
Range Nine
Option Exercise Price \| $ / shares	$ 1.20
Options Outstanding	274,000
Remaining Contractual Life (in years)	3 years 6 months 18 days
Options Exercisable	274,000
Range Ten
Option Exercise Price \| $ / shares	$ 1.59
Options Outstanding	25,000
Remaining Contractual Life (in years)	4 years 4 months 9 days
Options Exercisable	25,000
Range Eleven
Option Exercise Price \| $ / shares	$ 2.10
Options Outstanding	238,767
Remaining Contractual Life (in years)	8 years 1 month 9 days
Options Exercisable	238,767
Range Twelve
Option Exercise Price \| $ / shares	$ 2.13
Options Outstanding	216,708
Remaining Contractual Life (in years)	6 years 10 months 17 days
Options Exercisable	216,708
Range Thirteen
Option Exercise Price \| $ / shares	$ 2.15
Options Outstanding	200,000
Remaining Contractual Life (in years)	8 years 11 months 12 days
Options Exercisable	200,000
Range Fourteen
Option Exercise Price \| $ / shares	$ 2.17
Options Outstanding	35,955
Remaining Contractual Life (in years)	7 years 4 months 9 days
Options Exercisable	32,958
Range Fifteen
Option Exercise Price \| $ / shares	$ 2.19
Options Outstanding	5,000
Remaining Contractual Life (in years)	8 years 18 days
Options Exercisable	3,333
Range Sixteen
Option Exercise Price \| $ / shares	$ 2.40
Options Outstanding	302,833
Remaining Contractual Life (in years)	4 years 10 months 13 days
Options Exercisable	302,833
Range Seventeen
Option Exercise Price \| $ / shares	$ 2.43
Options Outstanding	61,250
Remaining Contractual Life (in years)	7 years 5 months 4 days
Options Exercisable	58,750
Range Eighteen
Option Exercise Price \| $ / shares	$ 2.45
Options Outstanding	98,000
Remaining Contractual Life (in years)	6 years 7 months 2 days
Options Exercisable	98,000
Range Nineteen
Option Exercise Price \| $ / shares	$ 2.49
Options Outstanding	78,435
Remaining Contractual Life (in years)	6 years 5 months 1 day
Options Exercisable	78,435
Range Twenty
Option Exercise Price \| $ / shares	$ 2.50
Options Outstanding	20,000
Remaining Contractual Life (in years)	5 years 4 months 17 days
Options Exercisable	20,000
Range Twenty One
Option Exercise Price \| $ / shares	$ 2.64
Options Outstanding	30,882
Remaining Contractual Life (in years)	7 years 7 months 6 days
Options Exercisable	25,734
Range Twenty Two
Option Exercise Price \| $ / shares	$ 2.67
Options Outstanding	33,194
Remaining Contractual Life (in years)	7 years 8 months 19 days
Options Exercisable	27,662
Range Twenty Three
Option Exercise Price \| $ / shares	$ 2.73
Options Outstanding	257,934
Remaining Contractual Life (in years)	9 years 11 months 8 days
Range Twenty Four
Option Exercise Price \| $ / shares	$ 2.99
Options Outstanding	8,000
Remaining Contractual Life (in years)	6 years 4 months 13 days
Options Exercisable	8,000
Range Twenty Five
Option Exercise Price \| $ / shares	$ 3.13
Options Outstanding	208,000
Remaining Contractual Life (in years)	5 years 10 months 13 days
Options Exercisable	208,000
Range Twenty Six
Option Exercise Price \| $ / shares	$ 3.50
Options Outstanding	8,000
Remaining Contractual Life (in years)	6 years 1 month 13 days
Options Exercisable	8,000

Stockholders' Equity - Restricted Common Stock Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Common stock issued upon exercise of stock options			319,550
Term number of years			5 years
Percentage of All Vested Shares Recipient Is Required To Hold During Employment In Order To Receive Award			75.00%
Granted (in shares)			257,934
Fair value of vested restricted common stock	$ 531,263	$ 347,672	$ 1,105,606	$ 482,327
Antidilutive securities amount			2,679,224
Minimum
Expected life (in years)			8 months 4 days
Maximum
Expected life (in years)			2 years 6 months 3 days
Restricted common stock
Number of shares of restricted common stock issued			308,000		5,184,592
Fair value of restricted common stock			$ 1,126,555
Fair value of shares vested			508,200		$ 2,427,309
Forfeited, Fair Value					$ 312,156
Forfeited, Number of shares					(279,489)
Amount recognized as expense related to stock issuance					$ 4,479,369
Non-vested stock	$ 2,445,756		$ 2,445,756		$ 2,711,661
Balance of non-vested shares	2,679,224		2,679,224		2,477,794
Granted Weighted Average Grant Date Fair Value			$ 2.26
Term number of years			5 years
Vesting period			3 years
Restricted stock to employees vested			178,570
Fair value of vested restricted common stock			$ 860,650		$ 7,503,186
Restricted common stock \| 2017 Plan
Number of shares of restricted common stock issued			250,000
Restricted common stock \| Minimum
Stock Repurchased Average Price Per Share			$ 2.24
Restricted common stock \| Maximum
Stock Repurchased Average Price Per Share			$ 2.73
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member}
Number of shares of restricted common stock issued			100,000
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 3.00
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member} \| Restricted common stock
Number of shares of restricted common stock issued			250,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Two [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 3.75
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Three [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 4.50
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Four [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 5.25
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Five [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 6.00
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Six [Member}
Volume Weighted Average Stock Price Per Share			$ 5.00
Restricted stock to employees vested			40,000
Vest Over Three Year Period One \| Restricted common stock
Number of shares of restricted common stock issued			130,000
Vesting period			3 years
Number of year(s) cliff vesting period			1 year
Vest Over Three and Four Year Period \| Restricted common stock
Fair value of vested restricted common stock			$ 352,450

Stockholders' Equity - Restricted common stock (Details) - Restricted common stock - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
Non-vested, Beginning balance	2,477,794
Granted Number of shares	380,000
Vested, Number of shares	(178,570)
Forfeited, Number of shares		(279,489)
Non-vested, Ending balance	2,679,224	2,477,794
Non-vested, Beginning balance	$ 2,711,661
Vested, Fair Value	(1,126,555)
Forfeited, Fair Value		$ 312,156
Non-vested, Ending balance	$ 2,445,756	$ 2,711,661
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value	$ 1.52
Granted Weighted Average Grant Date Fair Value	2.26
Vested Weighted Average Grant Date Fair Value	2.08
Non-vested, Ending Balance Weighted Average Grant Date Fair Value	$ 1.59	$ 1.52

Stockholders' Equity - Repurchases of our common stock (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023	Feb. 09, 2021
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs	$ 82,347		$ 82,347		$ 151,095
Average Price Paid per Share			$ 2.54
Repurchase of common stock	$ (22,613)	$ (30,667)	$ (68,748)	$ (48,729)
Publicly Announced Plans Or Programs
Share Price						$ 4.00
Maximum
Amount of stock authorized for repurchase						$ 400,000
Common Stock
Total Number of Shares Purchased	8,501	16,141	27,104	25,800
Repurchase of common stock	$ (8)	$ (16)	$ (27)	$ (25)

Acquisitions - Additional Information (Details)			6 Months Ended
Acquisitions - Additional Information (Details)	Dec. 01, 2023 USD ($)	Jul. 28, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Jun. 30, 2023 USD ($)
Asset Acquisition, Contingent Consideration [Line Items]
Payment for non-refundable deposit for asset acquisition			$ 0	$ 297,450	€ 300,000
Contingent consideration paid			64,578
Intangible assets			10,806,487
Goodwill			$ 16,451,937			$ 0
Estimated average useful life			10 years
Bonus Amount
Asset Acquisition, Contingent Consideration [Line Items]
Contingent consideration			$ 88,522
Resolute AI
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquried		100.00%
Purchase consideration, net of cash acquired		$ 4,600,000
Initial payment			2,700,000
Contingent earnout fair value			1,600,000
Multiplying factor for calculation of earnout		3.5
Enterprise value		$ 3,400,000
Receivables			200,000
Other assets			100,000
Goodwill			3,200,000
Payables			200,000
Deferred revenue			600,000
Other liabilities			200,000
Resolute AI \| Developed technology and customer relationships
Asset Acquisition, Contingent Consideration [Line Items]
Intangible assets			$ 2,100,000
Resolute AI \| Developed technology and customer relationships \| Minimum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			8 years
Resolute AI \| Developed technology and customer relationships \| Maximum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			10 years
Scite
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquried	100.00%
Purchase consideration, net of cash acquired	$ 20,900,000
Initial payment	7,200,000
Initial payments in stock	6,300,000
Initial payment hold back	$ 200,000
Contingent earnout fair value			$ 7,200,000
Receivables			100,000
Intangible assets			8,900,000
Goodwill			13,100,000
Deferred revenue			$ 1,200,000
Scite \| Minimum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			3 years
Scite \| Maximum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			10 years
Scite \| Developed technology and customer relationships \| Minimum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			3 years
Scite \| Developed technology and customer relationships \| Maximum
Asset Acquisition, Contingent Consideration [Line Items]
Estimated average useful life			10 years
2023
Asset Acquisition, Contingent Consideration [Line Items]
Payment of bonus amount			$ 96,121
2024
Asset Acquisition, Contingent Consideration [Line Items]
Payment of bonus amount			$ 42,911

Acquisitions - Pro Forma Operating Results (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Acquisitions
Revenue	$ 11,033,441	$ 8,793,998	$ 21,834,349	$ 17,663,493
Cost of revenue	5,877,494	5,363,807	11,967,550	10,742,750
Gross profit	5,155,947	3,430,191	9,866,799	6,920,743
Total operating expenses	5,524,052	4,031,029	11,197,427	7,461,089
Loss from operations	(368,105)	(600,838)	(1,330,628)	(540,346)
Other income	376,426	74,695	516,737	113,764
Income (loss) from operations before provision for income taxes	8,321	(526,143)	(813,891)	(426,582)
Provision for income taxes	(10,057)	(782)	(39,459)	(4,915)
Pro Forma Net loss	$ (1,736)	$ (526,925)	$ (853,350)	$ (431,497)
Pro Forma Net loss per weighted average share, basic (in dollars per share)	$ 0.00	$ (0.02)	$ (0.03)	$ (0.02)
Pro Forma Net loss per weighted average share, diluted (in dollars per share)		$ (0.02)	$ (0.03)	$ (0.02)

Subsequent Events (Details) - shares		6 Months Ended
Subsequent Events (Details) - shares	Jan. 05, 2024	Dec. 31, 2023
Common stock issued upon exercise of stock options		319,550
Subsequent Event
Common stock issued upon exercise of stock options	7,500
Common Stock \| Subsequent Event
Common stock issued upon exercise of stock options	909